A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia.

mezagitamab (TAK-079) - Takeda

http://www.ncbi.nlm.nih.gov/pubmed/41950473

; Andrea Patriarca; Antonia Syrigou; Atanas Radinoff; David J Kuter; Donald L Yee; Emily Skelton; Katsuhiro Miura; Katya Sapunarova; Parth Patwari; Renchi Yang; Scarlett Wang; Van Anh Nguyen

Apr 9, 2026